Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceutical days the FDA has approved a...

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceutical days the FDA has approved a broader indication for Zytiga. The drug, in combination with prednisone, may now be used earlier in the treatment continuum, before the use of chemotherapy. Zytiga also received a positive opinion for an expanded indication from the EMA and is under review by other health authorities worldwide.